HuGE Literature Finder
Records 1-5
|
Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array.
European journal of clinical pharmacology 2018 Jun . Kalra Sourav, Kaur Raman Preet, Ludhiadch Abhilash, Shafi Gowhar, Vashista Rajesh, Kumar Raj, Munshi Anja |
|
Associations between ALDH1A1 polymorphisms, alcohol consumption, and mortality among Hispanic and non-Hispanic white women diagnosed with breast cancer: the Breast Cancer Health Disparities Study.
Breast cancer research and treatment 2018 Apr 168 (2): 443-455. Xia Zhiyu, Baumgartner Kathy B, Baumgartner Richard N, Boone Stephanie D, Hines Lisa M, John Esther M, Wolff Roger, Slattery Martha L, Connor Avonne |
|
Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer.
The pharmacogenomics journal 2013 Sep . Yao S, Sucheston LE, Zhao H, Barlow WE, Zirpoli G, Liu S, Moore HC, Thomas Budd G, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Livingston RB, Albain KS, Hayes DF, Ambrosone CB |
|
Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.
Journal of human genetics 2009 Oct 54 (10): 564-71. Low Siew-Kee, Kiyotani Kazuma, Mushiroda Taisei, Daigo Yataro, Nakamura Yusuke, Zembutsu Hitos |
|
Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
Pharmacogenetics and genomics 2007 Jun 17 (6): 431-45. Nakajima Miki, Komagata Sayaka, Fujiki Yuto, Kanada Yoshihiro, Ebi Hiromichi, Itoh Kuniaki, Mukai Hirofumi, Yokoi Tsuyoshi, Minami Hirono |
- Page last reviewed:Oct 1, 2020
- Page last updated:Feb 24, 2021
- Content source: